Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca’s Soriot Outlines Epanova Approach, Reviews Tough First Year As CEO

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca’s two-pronged approach to get its experimental fish oil-based heart drug Epanova approved by U.S. regulators is on track according to CEO Pascal Soriot. But an FDA Advisory Committee’s negative recommendation for Amarin’s similar drug, Vascepa, likely means the second step, seeking a label expansion for Epanova in a broader, less seriously ill population, will have to await full outcomes data.


Related Content

AstraZeneca’s Epanova: Third In Omega-3 Market, Potentially First With Larger Population Claim
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance
Novo Nordisk Looks Ahead After Tresiba Setback, Bets Against Biosimilars
New Cholesterol Guidelines Follow Long History Of Failed Outcomes Trials
Cholesterol Drug Approvals May Hinge On Outcomes Studies; FDA Rejects Diabetes-style Tiered Trials
AZ’s MedImmune Buys Spirogen To Boost Oncology ADC Capability
$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership
Problems With Biomarkers: A Tale of Three Drugs


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts